

## Bicycle Therapeutics to Present at the Jefferies 2019 London Healthcare Conference

November 14, 2019

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Nov. 14, 2019-- <u>Bicycle Therapeutics plc</u> (NASDAQ: BCYC), a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (*Bicycle*<sup>®</sup>) technology, today announced that management will present at the Jefferies 2019 London Healthcare Conference on Wednesday, November 20, 2019 at 2:40 p.m. GMT (9:40 a.m. ET) in London, England.

A live webcast of the presentation can be accessed in the Investors & Media section of Bicycle's website at <a href="www.bicycletherapeutics.com">www.bicycletherapeutics.com</a>. An archived replay of the webcast will be available for 90 days following the presentation date.

## **About Bicycle Therapeutics**

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as *Bicycles*<sup>®</sup>, for diseases that are underserved by existing therapeutics. *Bicycles* are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making *Bicycles* attractive candidates for drug development. Bicycle's lead product candidate, BT1718, a *Bicycle* Toxin Conjugate (BTC) that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial in collaboration with the Centre for Drug Development of Cancer Research UK. Bicycle is also evaluating BT5528, a second-generation BTC targeting EphA2, in a Company-sponsored Phase I/II study. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191114005252/en/

Source: Bicycle Therapeutics plc

**Investor and Media Contact:** 

Bicycle Therapeutics Maren Killackey maren.killackey@bicycletx.com +1-617-203-8300